Edgewise Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Edgewise Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||
| current assets | ||||||||||||||||||
| cash and cash equivalents | 43,404,000 | 49,921,000 | 41,666,000 | 44,806,000 | 43,485,000 | 30,264,000 | 86,097,000 | 32,957,000 | 31,807,000 | 48,230,000 | 21,993,000 | 109,747,000 | 18,341,000 | 34,453,000 | 15,566,000 | 10,571,000 | 50,404,000 | 221,036,000 |
| marketable securities, available for sale | 550,588,000 | 386,466,000 | 428,504,000 | 447,730,000 | 468,266,000 | 502,495,000 | 232,296,000 | 256,740,000 | 278,121,000 | 279,722,000 | 329,954,000 | 255,075,000 | 230,054,000 | 231,380,000 | 265,223,000 | 279,913,000 | 248,747,000 | 88,835,000 |
| prepaid expenses and other assets | 9,263,000 | 6,791,000 | 5,313,000 | 6,900,000 | 7,690,000 | 8,668,000 | 8,604,000 | 8,224,000 | 7,069,000 | 5,411,000 | 5,052,000 | 5,317,000 | 4,948,000 | 2,784,000 | 2,984,000 | 2,758,000 | 3,818,000 | 674,000 |
| total current assets | 603,255,000 | 443,178,000 | 475,483,000 | 499,436,000 | 519,441,000 | 541,427,000 | 326,997,000 | 297,921,000 | 316,997,000 | 333,363,000 | 356,999,000 | 370,139,000 | 253,343,000 | 268,617,000 | 283,773,000 | 293,242,000 | 302,969,000 | 310,545,000 |
| | ||||||||||||||||||
| property and equipment | 8,595,000 | 8,990,000 | 9,503,000 | 9,966,000 | 9,897,000 | 10,184,000 | 10,443,000 | 10,679,000 | 10,856,000 | 10,396,000 | 8,533,000 | 5,428,000 | 2,920,000 | 2,224,000 | 1,614,000 | 1,535,000 | 1,084,000 | 1,008,000 |
| operating lease right-of-use asset | 1,484,000 | 1,528,000 | 1,569,000 | 1,618,000 | 2,047,000 | 2,195,000 | 2,247,000 | 2,297,000 | 2,353,000 | 2,390,000 | 1,318,000 | 1,322,000 | 1,571,000 | 2,130,000 | ||||
| other non-current assets | 695,000 | 262,000 | 262,000 | 262,000 | 348,000 | 467,000 | 419,000 | 251,000 | 251,000 | 264,000 | 447,000 | 559,000 | 548,000 | 295,000 | 201,000 | |||
| total assets | 613,334,000 | 454,391,000 | 486,817,000 | 511,282,000 | 531,647,000 | 553,806,000 | 340,035,000 | 311,364,000 | 330,625,000 | 346,400,000 | 367,101,000 | 377,153,000 | 257,399,000 | 272,745,000 | 285,233,000 | 294,448,000 | 303,493,000 | 311,245,000 |
| liabilities and stockholders' equity | ||||||||||||||||||
| current liabilities | ||||||||||||||||||
| accounts payable | 8,320,000 | 8,789,000 | 5,579,000 | 5,649,000 | 6,801,000 | 4,723,000 | 4,025,000 | 5,318,000 | 3,781,000 | 3,875,000 | 6,105,000 | 5,757,000 | 2,828,000 | 5,340,000 | 3,843,000 | 2,292,000 | 2,816,000 | 1,621,000 |
| accrued compensation | 5,636,000 | 3,974,000 | 10,056,000 | 6,185,000 | 4,244,000 | 2,924,000 | 5,695,000 | 4,408,000 | 3,125,000 | 2,074,000 | 4,032,000 | 2,704,000 | 2,024,000 | 1,346,000 | 2,797,000 | 2,030,000 | 1,373,000 | 672,000 |
| accrued other incomes | 5,936,000 | 7,351,000 | 7,229,000 | 6,131,000 | 5,143,000 | 5,969,000 | 6,071,000 | 5,681,000 | 6,622,000 | 5,969,000 | 5,840,000 | 4,626,000 | 4,260,000 | 3,318,000 | 3,881,000 | 4,432,000 | 2,550,000 | 2,558,000 |
| operating lease liability, current portion | 1,004,000 | 1,001,000 | 996,000 | 992,000 | 988,000 | 984,000 | 980,000 | 931,000 | 872,000 | 797,000 | 608,000 | 209,000 | 104,000 | |||||
| total current liabilities | 20,896,000 | 21,115,000 | 23,860,000 | 18,957,000 | 17,176,000 | 14,600,000 | 16,771,000 | 16,338,000 | 14,400,000 | 12,715,000 | 16,585,000 | 13,303,000 | 9,216,000 | 10,004,000 | 10,521,000 | 8,754,000 | 6,739,000 | 4,851,000 |
| operating lease liability, net of current portion | 3,367,000 | 3,557,000 | 3,741,000 | 3,448,000 | 3,997,000 | 4,265,000 | 4,434,000 | 4,599,000 | 4,770,000 | 4,845,000 | 3,800,000 | 2,387,000 | 1,636,000 | |||||
| total liabilities | 24,263,000 | 24,672,000 | 27,601,000 | 22,405,000 | 21,173,000 | 18,865,000 | 21,205,000 | 20,937,000 | 19,170,000 | 17,560,000 | 20,385,000 | 15,749,000 | 11,044,000 | 12,389,000 | 10,850,000 | 9,049,000 | ||
| commitments and contingencies | ||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||
| common stock | 10,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 7,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 |
| additional paid-in capital | 1,044,346,000 | 848,683,000 | 837,363,000 | 826,731,000 | 816,304,000 | 809,081,000 | 563,487,000 | 505,465,000 | 500,903,000 | 496,523,000 | 492,665,000 | 488,762,000 | 356,373,000 | 353,903,000 | 351,852,000 | 349,682,000 | 348,097,000 | 347,405,000 |
| accumulated other comprehensive income | 204,000 | 401,000 | 420,000 | 1,051,000 | -1,054,000 | -861,000 | 99,000 | |||||||||||
| accumulated deficit | -455,489,000 | -419,374,000 | -378,576,000 | -338,914,000 | -304,785,000 | -273,288,000 | -244,763,000 | -214,620,000 | -188,907,000 | -167,438,000 | -144,600,000 | -125,185,000 | -107,687,000 | -91,620,000 | -76,960,000 | -64,264,000 | -51,315,000 | -40,962,000 |
| total stockholders' equity | 589,071,000 | 429,719,000 | 459,216,000 | 488,877,000 | 510,474,000 | 534,941,000 | 318,830,000 | 290,427,000 | 311,455,000 | 328,840,000 | 346,716,000 | 361,404,000 | 246,355,000 | 260,356,000 | 274,383,000 | 285,399,000 | 296,754,000 | |
| total liabilities and stockholders' equity | 613,334,000 | 454,391,000 | 486,817,000 | 511,282,000 | 531,647,000 | 553,806,000 | 340,035,000 | 311,364,000 | 330,625,000 | 346,400,000 | 367,101,000 | 377,153,000 | 257,399,000 | 272,745,000 | ||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of december 31, 2023 and december 31, 2022 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||
| accumulated other comprehensive loss | -424,000 | -547,000 | -251,000 | -1,355,000 | -2,179,000 | -2,336,000 | -1,932,000 | -514,000 | -24,000 | -33,000 | -54,000 | |||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||
| other long term liabilities | 192,000 | 187,000 | 329,000 | 295,000 | ||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of december 31, 2022 and december 31, 2021 | ||||||||||||||||||
| short-term debt | 7,000 | |||||||||||||||||
| long-term debt | 59,000 | |||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized as of september 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively | ||||||||||||||||||
| less: accumulated depreciation | -882,000 | -785,000 | -702,000 | -624,000 | -560,000 | -509,000 | ||||||||||||
| total property and equipment | 2,038,000 | 1,439,000 | 912,000 | 911,000 | 524,000 | 499,000 | ||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized as of june 30, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively | ||||||||||||||||||
| operating lease long-term liability | 2,198,000 | |||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares authorized as of march 31, 2022 and december 31, 2021, respectively; no shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively | ||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders' equity | ||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||
| series a preferred stock, .0001 par value, no shares and 15,500,000 shares authorized, no shares and 8,187,100 shares issued and outstanding with an aggregate liquidation preference of 0 and 15,500 as of december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-1 preferred stock, .0001 par value, no shares and 14,934,484 shares authorized, no shares and 7,888,392 issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-2 preferred stock, .0001 par value, no shares and 12,358,305 shares authorized, no shares and 6,527,654 shares issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series c preferred stock, .0001 par value, no shares and 24,525,629 shares authorized, no shares and 12,954,423 shares issued and outstanding with aggregate liquidation preference of 0 and 95,000 as of december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| total convertible preferred stock | ||||||||||||||||||
| stockholders' equity | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares and no shares authorized as of december 31, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of december 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders' equity | 285,233,000 | 294,448,000 | 303,493,000 | 311,245,000 | ||||||||||||||
| series a preferred stock, .0001 par value, no shares and 15,500,000 shares authorized, no shares and 8,187,100 shares issued and outstanding with an aggregate liquidation preference of 0 and 15,500 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-1 preferred stock, .0001 par value, no shares and 14,934,484 shares authorized, no shares and 7,888,392 issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-2 preferred stock, .0001 par value, no shares and 12,358,305 shares authorized, no shares and 6,527,654 shares issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series c preferred stock, .0001 par value, no shares and 24,525,629 shares authorized, no shares and 12,954,423 shares issued and outstanding with aggregate liquidation preference of 0 and 95,000 as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares and no shares authorized as of september 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series a preferred stock, .0001 par value, no shares and 15,500,000 shares authorized, no shares and 8,187,100 shares issued and outstanding with an aggregate liquidation preference of 0 and 15,500 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-1 preferred stock, .0001 par value, no shares and 14,934,484 shares authorized, no shares and 7,888,392 issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-2 preferred stock, .0001 par value, no shares and 12,358,305 shares authorized, no shares and 6,527,654 shares issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series c preferred stock, .0001 par value, no shares and 24,525,629 shares authorized, no shares and 12,954,423 shares issued and outstanding with aggregate liquidation preference of 0 and 95,000 as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares and no shares authorized as of june 30, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series a preferred stock, .0001 par value, no shares and 15,500,000 shares authorized, no shares and 8,187,100 shares issued and outstanding with an aggregate liquidation preference of 0 and 15,500 as of march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-1 preferred stock, .0001 par value, no shares and 14,934,484 shares authorized, no shares and 7,888,392 issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series b-2 preferred stock, .0001 par value, no shares and 12,358,305 shares authorized, no shares and 6,527,654 shares issued and outstanding with an aggregate liquidation preference of 0 and 25,075 as of march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| series c preferred stock, .0001 par value, no shares and 24,525,629 shares authorized, no shares and 12,954,423 shares issued and outstanding with aggregate liquidation preference of 0 and 95,000 as of march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| preferred stock, .0001 par value per share; 200,000,000 shares and no shares authorized as of march 31, 2021 and december 31, 2020, respectively; no shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively | ||||||||||||||||||
| total stockholders' (deficit) equity | 306,394,000 |
We provide you with 20 years of balance sheets for Edgewise Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Edgewise Therapeutics. Explore the full financial landscape of Edgewise Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Edgewise Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.